NeoStem’s Cancer Immunotherapy Experts to Present at Novel Cancer Therapeutics Summit 2014

NEW YORK, June 30, Jun 30, 2014 (GLOBE NEWSWIRE via COMTEX) NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that two of its leading cancer immunotherapy experts, Dr. Andrew Pecora, Chief Visionary Officer, NeoStem; and Dr. Robert O. Dillman, Vice President, Oncology of the Company s wholly-owned subsidiary, NeoStem Oncology LLC., will give presentations at the sub-conferences of the Novel Cancer Therapeutics Summit in Boston, Massachusetts on Monday, July 7. Dr. Pecora will speak about highlights of NeoStem s Targeted Immunotherapy Program that focuses on patient-specific immunotherapies for the treatment of late stage cancers, including NeoStem s expected launch later this year of a pivotal Phase 3 trial for Melapuldencel-T, its lead product candidate. Dr. Dillman will speak about whether the best source of tumor-associated antigens may be autologous tumor cells that self-renew in tissue culture. 3 Annual Oncology Partnering and Deal Ma
http://bit.ly/1mAsrw3